Welcome to our dedicated page for Ionis Pharmaceuticals news (Ticker: $IONS), a resource for investors and traders seeking the latest updates and insights on Ionis Pharmaceuticals stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ionis Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ionis Pharmaceuticals's position in the market.
Ionis Pharmaceuticals, Inc. reported its first quarter 2024 financial results, highlighting positive Phase 3 data for HAE and regulatory submissions for olezarsen. The company remains on track to achieve its 2024 financial guidance, with revenue totaling $119 million and operating expenses increasing due to strategic investments in new products. Ionis' cash and short-term investments stand at $2.2 billion, supporting planned upcoming launches and reaffirmed financial guidance.